Global Retirement Partners LLC Trims Stake in GSK plc (NYSE:GSK)

Global Retirement Partners LLC lowered its position in GSK plc (NYSE:GSK) by 8.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 36,847 shares of the pharmaceutical company’s stock after selling 3,263 shares during the period. Global Retirement Partners LLC’s holdings in GSK were worth $1,246,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC lifted its position in GSK by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 11,764 shares of the pharmaceutical company’s stock valued at $481,000 after buying an additional 3,405 shares during the period. Foundations Investment Advisors LLC lifted its position in GSK by 4.8% during the 3rd quarter. Foundations Investment Advisors LLC now owns 10,122 shares of the pharmaceutical company’s stock valued at $414,000 after acquiring an additional 466 shares during the period. Sequoia Financial Advisors LLC lifted its position in GSK by 2.6% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 22,937 shares of the pharmaceutical company’s stock valued at $938,000 after acquiring an additional 577 shares during the period. Eastern Bank bought a new stake in GSK during the third quarter worth about $26,000. Finally, International Assets Investment Management LLC grew its holdings in GSK by 3,991.9% in the third quarter. International Assets Investment Management LLC now owns 226,487 shares of the pharmaceutical company’s stock worth $92,590,000 after purchasing an additional 220,952 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Down 0.9 %

GSK stock opened at $36.62 on Friday. The stock has a market capitalization of $75.91 billion, a P/E ratio of 23.03, a P/E/G ratio of 1.11 and a beta of 0.64. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.92. The business has a fifty day moving average price of $34.61 and a 200-day moving average price of $37.36.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Equities analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.29%. GSK’s dividend payout ratio is 93.08%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GSK. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Morgan Stanley assumed coverage on GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Finally, Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and cut their price objective for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Seven analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.